流感最新消息N°550

GLOBAL INFLUENZA SURVEILLANCE AND RESPONSE SYSTEM (GISRS) RSV SARS-CoV-2 Influenza Co-circulation SUMMARY (Based on data reported to WHO for week 42, ending 19 October 2025) Globally, influenza and SARS-CoV-2 activity remained low in week 42. At these low levels of circulation, SARS-CoV-2 continues to be more predominantthan influenza overall this week. SARS-CoV-2 predominated in the temperate and subtropical regions of the northern hemisphere. Influenza was predominantin the tropics, with influenza positivity around 10%, and in the temperate and subtropical areas of the southern hemisphere where influenza percentpositivity was below 10%. [Figures 1a, 1b, 1c and 1d] . qInfluenza Globally, influenza activity remained low, with influenza A viruses continuing to predominate. [Figure 2] In the northern hemisphere, influenza activity remained low and stable in most countries. Influenza percent positivity was elevated in Central Americaand the Caribbean, Northern and Eastern Africa, and Northern Europe, with levels over 30% in Western and Middle Africa, Western, Southern andSouth-East Asia. An increase in activity compared to the previous week was observed in countries in Western and Eastern Africa, Northern Europe,Western, Southern and South-East Asia. [Figures 3 and 4] In the southern hemisphere, influenza activity remained low and stable in most countries with elevated positivity (>10%) in single countries inTemperate South America and Eastern Africa and percent positivity over 30% in a single country in South-East Asia. No increasing trends in activitycompared to the previous week were seen in countries the Southern Hemisphere. [Figures 3 and 4] In the transmission zones with elevated positivity, influenza A(H1N1)pdm09 predominated in Northern and Middle Africa whereas influenza A(H3N2)was the predominant circulating subtype Northern Europe, Western, Southern and South-East Asia and Temperate South America.InfluenzaA(H1N1)pdm09 and influenza A(H3N2) were codominant in Western and Eastern Africa and influenza A(H1N1)pdm09 and influenza B werecodominant in Central America and the Caribbean. [Figures 5 and 6] qSARS-CoV-2Globally, SARS-CoV-2 positivity increased but remained at low levels, with some countries reporting elevated positivity (>10%) in Central America and the Caribbean, Tropical South America, South-West and Eastern Europe, and Eastern Asia. Percent positivity was over 30% in one country inSouth-West Europe. Small increases in activity were reported in single countries in Eastern Africa and South-West Europe. [Figures 7 and 8] qRespiratory Syncytial Virus (RSV)RSV percent positivity remained elevated in some countries in Western and Eastern Africa, and over 30% in two countries in Central America and the Caribbean. RSV positivity remained stable across most countries, with increases in activity in a few countries in Central America and the Caribbean.[Figures 9 and 10] RSV and influenza activity were both elevated in a few countries of Central America and the Caribbean. Co-circulation of influenza and SARS-CoV-2 1a) Weekly numbers of influenza and SARS-CoV-2 virus specimens tested and percent positivity at the global level(last 12 months) 1c) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in Tropical areas 1b) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in Northern hemispheretemperate and subtropical areas 1d) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in Southern hemispheretemperate and subtropical areas Influenza 2) Weekly numbers of influenza virus positive specimens by type and subtype and percent positivity at the globallevel (last 12 months) 4) Change in proportions of specimens that testedpositive for influenza (year-week:2025-42) 3) Proportions of specimens that tested positive forinfluenza (year-week:2025-42) 6) Weekly distribution of influenza virus types andsubtypes by geographic zone (last 12 months) 5) Proportions of influenza virus types and subtypes byinfluenza transmission zones (year-week:2025-42) SARS-CoV-2 7) Proportions of specimens that tested positive forSARS-CoV-2 (year-week:2025-42) 8) Change in proportions of specimens that testedpositive for SARS-CoV-2 (year-week:2025-42) Respiratory syncytial virus 9) Proportions of specimens that tested positive for RSV(year-week:2025-42) 10) Change in proportions of specimens that testedpositive for RSV (year-week:2025-42) Additional information Data and methods The data presented in this report originates from virologic surveillance conducted by countries, areas, and territories (CATs) andsubmitted to WHO FluNet through participation or collaboration with the Global Influenza Surveillance and Response System(GISRS). These CATs employ diverse methodologies to monitor respiratory virus activity, which may result in variations betweenthis report and other surveillance summaries publ